Introduction: Patients with advanced lung cancer have a poor prognosis, but both chemotherapy and early palliative care (EPC) have been shown to improve survival and quality of life (QOL). The relationship between palliative care and receipt of chemotherapy receipt is understudied. We sought to determine if EPC is associated with chemotherapy receipt and intensity among patients with advanced stage lung cancer.
Introduction
In 2018, more than 234,000 Americans will be diagnosed with lung cancer, and the majority of these will be advanced-stage disease. 1, 2 Despite advances in treatment *Corresponding author.
for advanced-stage patients, prognosis is poor, with median survival of less than 1 year. 2, 3 Palliative chemotherapy is initiated in patients with advanced lung cancer with a goal to improve quality of life (QOL) and survival, as it cannot cure disease. The American Society of Clinical Oncology (ASCO) recommends against chemotherapy in patients with an Eastern Cooperative Oncology Group performance status (PS) score of 3 or greater and in those for whom there was no evidence of clinical value, as it is both harmful and wasteful. [4] [5] [6] Unfortunately, a considerable proportion of patients with poor PS continue to receive chemotherapy, which is considered low-quality cancer care. 4, 7 High-intensity chemotherapy among patients with advanced lung cancer has not been well-defined. However, the National Comprehensive Cancer Network recommends no more than 4 cycles of a platinum-based doublet as the initial treatment in most patients with advanced lung cancer. 8, 9 Additionally, each subsequent line of chemotherapy has diminishing returns with one study showing third-and fourth-line response rates of 2% and 0%, respectively. 10 Treatment with triplet therapy (bevacizumab or cetuximab combination) has a very high toxicity profile with inconsistent survival benefit, particularly among older patients. 11 Also, whereas erlotinib is beneficial for a select group of patients with EGFR mutations, before accessible confirmatory EGFR testing, response rates were very low and therapy was considered salvage. 12, 13 Chemotherapy near the end of life, namely in the last 14 and 30 days of life, is detrimental to patient QOL, satisfaction, and increases hospitalization rates. [14] [15] [16] [17] [18] Early palliative care (EPC) is recommended by ASCO guidelines as it improves symptom burden and QOL, and may reduce aggressive end-of-life care and increase survival. 19, 20 However, the mechanisms of these benefits are unclear. It has been hypothesized that palliative care may confer benefits via enhanced communication of patient preferences and symptom management, thus helping reduce unintended harms of high-intensity treatment leading to a potential survival benefit. 21, 22 Alternatively, another possibility is that the benefits of EPC are related to more judicious use of chemotherapy or high-intensity chemotherapy only for patients who are likely to derive benefit. The aims of this study were to characterize chemotherapy receipt among a national population of patients with advanced-stage lung cancer in an integrated health system, and to determine the associations between EPC and both chemotherapy and high-intensity chemotherapy receipt.
Methods
Retrospective cohort study of Veterans diagnosed with advanced stage (IIIB or IV) lung cancer identified using the Veterans Affairs Central Cancer Registry (VACCR) between January 1, 2007, and December 31, 2013 . VACCR registrars' abstract patient cases including sociodemographic, tumor characteristics, and treatments received in accordance with the Commission on Cancer. 23 Other patient characteristics at the time of cancer diagnosis were compiled from the Veterans Affairs Corporate Data Warehouse which integrates clinical and administrative data. Cancer staging was determined using VACCR data and is based on the American Joint Committee on Cancer TNM staging system. 2 Extensivestage SCLC was categorized as stage IV. Patients with nonprimary lung cancer, unknown stage or histology, and initial chemotherapy receipt 180 days or more after cancer diagnosis were excluded. Late chemotherapy receipt (180 days or more after diagnosis) was not considered part of the initial treatment plan. Additional cohort characteristics have been described previously. 24 Exposure EPC. Palliative care was defined as at least one specialty palliative care encounter received after a lung cancer diagnosis determined using Veterans Affairs (VA) administrative inpatient, outpatient, and fee-based encounter data. Current palliative care guidelines recommend EPC, although the timing of this has not been consistently defined. Therefore, in this study, EPC was defined as an initial palliative care encounter received within 90 days of a lung cancer diagnosis based on previous studies. 22, [25] [26] [27] [28] Outcomes Chemotherapy Receipt. Chemotherapy receipt was obtained from the inpatient and outpatient pharmacy files in the Corporate Data Warehouse. 29 Chemotherapy receipt was defined as any oral or intravenous antineoplastic therapy received after a lung cancer diagnosis. Receipt was captured as chemotherapy type, dose, and route administered. The following drugs were considered chemotherapy: bevacizumab, carboplatin, cetuximab, cisplatin, crizotinib, cyclophosphamide, docetaxel, doxorubicin, epirubicin, erlotinib, etoposide, gemcitabine, ifosfamide, irinotecan, nanoparticle albumin-bound paclitaxel, paclitaxel, pemetrexed, temozolamide, topotecan, vinblastine, and vinorelbine. The following agents were included, but not received by patients in our cohort: afatinib, alectinib, cabozatinib, ceritinib, gefitinib, ipilimumab, nivolumab, pembrolizumab, necitumumab, ramucirumab, sorafenib, teniposide, vincristine, and vindesine.
High-Intensity Chemotherapy. High-intensity chemotherapy definitions were determined a priori and were based on ASCO guidelines and clinical trial data as described below:
1. For more than 4 cycles of a platinum-based doublet, each cycle of platinum doublet was defined as receipt of carboplatin or cisplatin with an associated doublet drug (e.g., cyclophosphamide, docetaxel, doxorubicin, epirubicin, etoposide, gemcitabine, ifosfamide, irinotecan, nanoparticle albumin-bound paclitaxel, paclitaxel, pemetrexed, vinblastine, or vinorelbine). Each platinum cycle was defined as receipt of cisplatin or carboplatin and its associated doublet drug 14 to 36 days after the initial platinum drug. Randomized controlled trials found chemotherapy beyond 3 to 4 courses conveyed no survival or QOL benefits in advanced NSCLC. [30] [31] [32] [33] 2. For three lines or more of chemotherapy, it was considered one line if at least one dose of a single antineoplastic drug (singlet) defined above, platinum doublet (doublet), or three-drug (triplet) chemotherapy (defined below) drug dose/combination was administered. An additional line of chemotherapy was then considered for each transition to a new chemotherapeutic agent for at least one dose. Doublet combinations were based on the platinum base and if one antineoplastic was changed, it was considered a different line. Similarly, triplet therapy was based on receipt of bevacizumab or cetuximab combined with a platinum-doublet; and if chemotherapy transitioned to doublet or singlet, it was considered a subsequent line. This definition was based on data showing response rates in advanced NSCLC decrease with each successive line of treatment. 10, 13, 34, 35 3. Triplet therapy was defined as having ever received bevacizumab or cetuximab combined with other neoplastic agents after a lung cancer diagnosis. The rationale for use of bevacizumab to define chemotherapy intensity is historically based on four randomized control trials showing that bevacizumab did not improve 1-year overall survival. 11 These randomized controlled trials showed increased risk of treatmentrelated death, especially in patients older than 65 years old. Cetuximab was also considered high intensity given its adverse safety profile and equivalent progression-free survival compared to safer alternatives. 36, 37 4. Receipt of erlotinib before January 1, 2011, was considered intensive therapy as it was not likely guided by mutation testing and there was no evidence of benefit in wild-type EGFR patients. 
Statistical Analysis
Descriptive statistics were used to characterize patient sociodemographics by chemotherapy receipt. Continuous data are presented as mean ± SD or median (interquartile range) and categorical variables as proportions. The association between EPC and receipt of chemotherapy was modeled using adjusted multivariable logistic regression. Chemotherapy high-intensity models only included those patients who received chemotherapy. Receipt of erlotinib included patients who received chemotherapy from 2007 to 2010. All regression models were adjusted for age, sex, race, marital status, income, tobacco use, year of cancer diagnosis, functional comorbidity index (FCI), Charlson comorbidity index (CCI), cancer stage, histology, and survival recorded at the time of diagnosis. 43, 44 Receipt of chemotherapy at the end of life (at 14 and 30 days) excluded patients alive for fewer than 14 days and for less than 30 days, respectively, and neither model was adjusted for survival. Sensitivity analyses were conducted to assess chemotherapy receipt using the following: (1) survival in overlapping intervals (i.e., 1 to 30 days, 1 to 60 days, 1 to 90 days, etc.); (2) excluding patients alive less than the mean of chemotherapy receipt (less than 60 days); and (3) timing of EPC before initial chemotherapy receipt or chemotherapy before EPC consult. Results were similar to the final models. Modeling used robust standard errors and statistical testing was two-sided with a threshold of p < 0.05. All analyses were done in Stata version-14 (StataCorp, College Station, Texas).
Results
Overall, 23,566 patients were diagnosed with advanced-stage lung cancer from 2007 to 2013; the mean age was 68 years, 98% were men, 71% were white, 57% were not married, and 56% were current smokers. Regarding tumor characteristics, 89% had stage IV disease and 69% were diagnosed with NSCLC (Table 1) . Among the entire cohort, 37% (n ¼ 8638) received EPC. Of those receiving EPC, the mean time from lung cancer diagnosis to first palliative care encounter was 26 days (SD: 24 days) and the mean time from first palliative care encounter to death was 105 days (SD: 200 days). In the entire cohort, 12% (n ¼ 2832) of patients received chemotherapy in the last 30 days and 6% (n ¼ 1365) of patients received chemotherapy in the last 14 days of life.
Chemotherapy Characteristics
Overall, 45% (n ¼ 10,501) of patients received any chemotherapy, 34% and 51% among those with and without EPC, respectively ( Table 2 ). The mean time from diagnosis of lung cancer to first chemotherapy cycle was 36 days (SD: 28 days) in those with EPC and 49 days (SD: 37 days) in those without EPC. Among patients who received chemotherapy, the first cycle received was most commonly a platinum-based doublet in each group.
The last chemotherapy cycle received was most often a platinum-based doublet in those with and without EPC, 57% versus 45%, respectively. The duration from last chemotherapy dose to death was shorter in those with EPC at 83 days (SD: 127 days) compared to 140 days (SD: 229 days) in those without EPC.
Any Chemotherapy and High-Intensity Chemotherapy Receipt
Comparing patients with and without EPC, those with EPC were less likely to receive any chemotherapy (adjusted odds ratio [AOR]: 0.55, 95% confidence interval [CI]: 0.51-0.58) ( Table 3) . Those with EPC were also less likely to receive more than 4 cycles of platinumbased doublet chemotherapy (AOR: 0.68, 95% CI: 0.60-0.77) and three or more lines of chemotherapy (AOR: 0.61, 95% CI: 0.53-0.71). Regarding chemotherapy regimens, triplet therapy (AOR: 0.68, 95% CI: 0.56-0.82) receipt occurred less often in those with EPC compared to those without EPC. Finally, erlotinib before 2011 (AOR: 0.66, 95% CI: 0.55-0.79) was also less likely to be received in the EPC group compared to the group without EPC. Surprisingly, patients with EPC were more likely to receive chemotherapy in the last 14 days (AOR: (3) (4) 2378 (28) 4457 (30) Severe (5) 2492 (29) 
Discussion
In a national cohort of patients with advanced lung cancer, EPC was associated with reduced receipt of chemotherapy. Additionally, EPC was associated with reduced receipt of high-intensity chemotherapy including 4 cycles of platinum-based therapy, three or more lines of chemotherapy, triplet therapy, and erlotinib before 2011, compared to patients without EPC. Surprisingly, EPC was associated with greater likelihood to receive chemotherapy at the very end of life. Among patients with advanced lung cancer, EPC may help optimize patient selection for receipt of any chemotherapy and especially high-intensity chemotherapy by changing the focus to patients' goals and QOL consistent with high-quality cancer care.
EPC is a key recommendation in ASCO's guidelines given its potential benefits to QOL and survival; however, the mechanisms of these benefits are largely unknown. Previous studies suggest better symptom control or improvements in mental health as the main drivers of benefits 20, 22, 45 However, recent research suggests that patients with advanced cancer undergoing second-line chemotherapy have decrements in their QOL, especially among those with good PS, and new chemotherapy initiation is less common when discussing treatment decisions. 46 ,47 Yet, the relationship between EPC and chemotherapy receipt is complex.
EPC may improve symptom control enabling patients to tolerate an increased number of cycles or lines of chemotherapy contributing to improved survival. 22, 48 Alternatively, as was found in our study, EPC was associated with reduced receipt of high-intensity chemotherapy, which can contribute to worse QOL and survival. Depending on a patient's suitability and preference for chemotherapy, according to their goals of care, either of these roles could explain the improved patient outcomes observed with initiation of EPC in previous studies. 22, 25 Patient selection of those likely to derive benefit from chemotherapy or high-intensity chemotherapy regimens is challenging. We observed an association between EPC and reduced receipt of high-intensity chemotherapy, and ours is one of the first studies to examine this relationship with such granular chemotherapy details. The explanations for the observed relationship are likely multifactorial and EPC has several potentially important roles regarding patient selection for chemotherapy receipt: (1) EPC may increase a patient's ability to cope with their illness and simultaneously improve collaboration with oncology and palliative care thereby making decisions about chemotherapy discontinuation more tolerable 47 ; (2) EPC may assist in a more accurate assessment of PS, identifying patients with lower ECOG scores, and providing a realistic assessment of potential benefits and harms of chemotherapy 49 ; (3) practitioners who consult palliative care specialists early may also be less likely to offer high-intensity care 50 ; and (4) more debilitated patients might generate earlier palliative care consults and inherently be less likely to receive higher-intensity chemotherapy. 51 Overall, our study highlights the importance of early integration of palliative care as part of a comprehensive cancer program given its potential benefit in guiding appropriate patient selection for chemotherapy receipt. The finding that EPC was associated with increased chemotherapy receipt in the last days of life was unexpected. The percentage of patients receiving chemotherapy close to death in our study was consistent with previously reported values in a study of veterans with cancer which was significantly less than received by fee-for-service Medicare patients with cancer. 52 Importantly, the VA allows veterans to receive concurrent hospice care and chemotherapy which may contribute to late chemotherapy receipt in the EPC group. 24 When we excluded patients with extremely shortened life expectancy, survival less than 90 days from diagnosis, the effect size for late chemotherapy receipt differences decreased, although significant differences persisted. EPC, when received close to cancer diagnosis, may be expected to have an impact on subsequent chemotherapy receipt and intensity. However, EPC may not actually reduce the likelihood of late chemotherapy as has been theorized but not extensively studied in real-world populations of patients. 15, 19, 20 A subanalysis of a randomized trial of EPC found reduced chemotherapy in the last 60 days of life; however, chemotherapy characteristics (e.g., regimen intervals, number of regimens, and dose intensity) were not compared due to significant sample heterogeneity. 48 This same trial found no differences in receipt of chemotherapy in the last 14 and 30 days of life between patients in the EPC and control groups. Our results were consistent with these findings and show that the relationship between palliative care and chemotherapy receipt at the very end of life deserves further examination.
There are study limitations. PS was not consistently available via a score (e.g., Eastern Cooperative Oncology Group); therefore, we relied on surrogate markers including age, cancer stage, histology, CCI, and FCI. There were few women included in the study, which limits generalizability. Chemotherapy cycle delays limited assessments of some chemotherapy types as irregular cycle intervals prevented accurate cycle frequency counts. Oncologists' reasons for chemotherapy delays or dose reductions were unavailable. Detailed chemotherapy data was limited to patients receiving cancer care within the VA centers, and some patients may have received additional chemotherapy outside of the VA centers. However, it is rare to initiate concomitant chemotherapy in multiple care settings. We studied specialty palliative care encounters, not referrals, and patients' preferences regarding palliative care were not captured. Palliative care delivered by nonpalliative care specialists (e.g., primary care clinicians) was not studied.
Conclusions
Among patients with advanced lung cancer in a national integrated healthcare system, EPC was associated with reduced odds of receiving any or high-intensity chemotherapy. EPC was also associated with increased receipt of chemotherapy at the very end of life. Early integration of palliative care may enhance patient selection for chemotherapy receipt by incorporating goals of care discussions, fostering better communication among the multidisciplinary care team, and setting realistic patient expectations for cancer treatment, leading to optimized patient selection of those most likely to derive benefit. Continued attention to the use of chemotherapy and high-intensity of chemotherapy in patients with advanced cancer is essential to improve the quality of comprehensive lung cancer care.
